Sherpa Healthcare Fund II GP

Sherpa targets growth-stage companies, primarily Series B and later rounds in the biopharma, medical device, and digital health sectors. This stage aligns with the capital-intensive clinical trial and regulatory approval phases where specialized underwriting is critical.

The firm is known to execute direct equity investments in portfolio companies requiring growth capital. There is no public evidence of an active fund-of-funds commitment strategy or secondary market participation for this specific vehicle.